Patient-Derived SNU Models for Personalized Gastric Cancer Treatment

Gastric cancer remains a significant global health burden, with marked heterogeneity in molecular subtypes, treatment response, and clinical outcomes. At Cytion, we recognize that the era of personalized medicine demands preclinical models that capture this diversity and enable patient-specific treatment optimization. SNU gastric cancer cell lines, established from a cohort of Korean patients with varied clinicopathological features, provide a unique resource for developing and validating personalized treatment strategies in this challenging malignancy.

Key Takeaways

• SNU gastric lines represent diverse molecular subtypes enabling precision medicine research
• Genetic profiling enables matching of cell line models to patient tumor characteristics
• Drug sensitivity profiling predicts response to targeted and conventional therapies
• Biomarker-driven treatment selection improves therapeutic outcomes
• Panel-based screening identifies optimal therapies for specific molecular contexts

Molecular Subtyping and Cell Line Selection

The Cancer Genome Atlas (TCGA) classification divides gastric cancer into four molecular subtypes with distinct biological features and therapeutic implications: EBV-positive, microsatellite instability-high (MSI-H), genomically stable (GS), and chromosomal instability (CIN). Effective personalized treatment requires models representing each subtype.

Our AGS Cells (300408) represent a well-characterized gastric adenocarcinoma model with defined genetic features enabling their use as surrogates for patient tumors with matching molecular profiles. AGS cells harbor characteristic mutations and gene expression patterns that can be correlated with drug sensitivity data.

Patient tumor molecular profiling through next-generation sequencing identifies actionable alterations including HER2 amplification, MET amplification, FGFR2 amplification, and microsatellite instability status. Cell line selection based on matching molecular features enables predictive drug screening most relevant to individual patient contexts.

Drug Sensitivity Profiling Approaches

High-throughput drug sensitivity screening across gastric cancer cell line panels generates comprehensive response profiles correlating drug sensitivity with molecular features. This approach identifies both predictive biomarkers for drug response and patient populations likely to benefit from specific therapies.

Standard cytotoxicity assays (MTT, CellTiter-Glo) performed across dose ranges generate IC50 values for hundreds of compounds. Sensitivity patterns cluster with molecular subtypes, revealing subtype-specific therapeutic vulnerabilities. For example, MSI-H lines often show enhanced sensitivity to immune checkpoint inhibitors and reduced sensitivity to 5-fluorouracil.

Combination drug matrices identify synergistic regimens that may improve outcomes beyond single-agent therapy. Systematic testing of chemotherapy plus targeted agent combinations reveals interactions that can be prioritized for clinical development.

Time-resolved cytotoxicity measurements using real-time impedance (xCELLigence) or live-cell imaging provide kinetic information beyond endpoint assays, distinguishing cytostatic from cytotoxic effects and identifying delayed responses.

Biomarker-Driven Treatment Selection

Predictive biomarkers enable rational treatment selection by identifying patients likely to respond to specific therapies. Gastric cancer has several established and emerging biomarkers guiding clinical practice.

HER2 amplification, present in approximately 15-20% of gastric cancers, predicts response to trastuzumab-containing regimens. Cell lines with HER2 amplification show exquisite sensitivity to HER2-targeted agents, validating this biomarker in preclinical models.

Microsatellite instability status predicts response to immune checkpoint inhibitors. MSI-H gastric cancers harbor high mutational burden and neoantigen load, promoting anti-tumor immunity. MSI-H cell line models enable mechanistic studies of immunotherapy response.

PD-L1 expression, while imperfect as a single biomarker, contributes to immunotherapy response prediction. Cell line PD-L1 expression can be correlated with sensitivity to checkpoint blockade in co-culture systems with immune effector cells.

Resistance Mechanism Characterization

Understanding resistance mechanisms is essential for developing strategies to overcome treatment failure. Drug-resistant cell line variants generated through chronic drug exposure model acquired resistance, while intrinsically resistant lines reveal primary resistance mechanisms.

Genomic and transcriptomic profiling of resistant cells identifies alterations driving resistance. Common mechanisms include target gene amplification or mutation, bypass pathway activation, and drug efflux transporter upregulation.

Functional CRISPR screens identify genes whose knockout sensitizes resistant cells to therapy, nominating combination partners that may overcome resistance. These genetic approaches complement pharmacological screens for resistance reversal strategies.

Recommended Products for Gastric Cancer Personalized Medicine Research:

• AGS Cells (300408) - Well-characterized gastric adenocarcinoma
• HGC-27 Cells (300436) - Undifferentiated gastric carcinoma
• DMEM High Glucose (820300a) - Standard culture medium
• Freeze medium CM-ACF (800650) - Cryopreservation solution